Mobile Button 搜索>
Pre-IND
Phase I
Phase II
Phase III
Registration
Marketed

血液增生疾病(血液腫瘤)

P1101
真性紅血球增生症 (EU)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

血液增生疾病(血液腫瘤)

P1101
真性紅血球增生症 (US, TW)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

血液增生疾病(血液腫瘤)

P1101
真性紅血球增生症 (JP, CN, KR)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

血液增生疾病(血液腫瘤)

P1101
血小板增生症 (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

血液增生疾病(血液腫瘤)

PEG-EPO
貧血症 (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

血液增生疾病(血液腫瘤)

PEG-GCSF
白血球缺乏症 (Global, exc US)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

感染疾病

P1101
C型肝炎基因第二型 (TW, KR, CN)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

感染疾病

P1101
B肝e抗原陽性 - 合併療法 (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

感染疾病

P1101 (orphan)
D型肝炎 / B型肝炎 (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

腫瘤疾病

Oraxol
乳癌 (TW, SG, VN)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

腫瘤疾病

Oraxol + Ramucirumab
胃癌 (Global)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

腫瘤疾病

P1101 + PD-1
HCC (Gloabl)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA

皮膚疾病

KX01
牛皮癬 (TW, CN, MY)
Pre-Clinical
Phase I
Phase II
Phase III
NDA
NDA